A
Aclaris Therapeutics D
D
ACRS
1.86000
USD
0.03
(1.64%)
مغلق
حجم التداول
42,055
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
201,497,925
الأخبار المقالات
العنوان: Aclaris Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.